1. The Cure Parkinson’s Trust and Parkinson’s community mourn the loss of their champion Tom Isaacs. Cure Parkinson’s Trust. June 19, 2017. www.cureparkinsons.org.uk/news/cpt-pd-community-mourns-the-loss. Accessed March 14, 2019; Tom Isaacs. The Times. July 5, 2017; Obituary.
2. Palfreman J. CPT Co founder Tom Isaacs featured in the Journal of Parkinson’s Disease. Cure Parkinson’s Trust. October 30, 2013. www.cureparkinsons.org.uk/News/cpt-co-founder-tom-isaacs-featured-in-the-journal-of-parkinsons-disease. Accessed March 27, 2019.
3. Our story. Cure Parkinson’s Trust. www.cureparkinsons.org.uk/our-story. Accessed March 27, 2019.
4. Palfreman J. CPT Co founder Tom Isaacs featured in the Journal of Parkinson’s Disease. Cure Parkinson’s Trust. October 30, 2013. www.cureparkinsons.org.uk/News/cpt-co-founder-tom-isaacs-featured-in-the-journal-of-parkinsons-disease. Accessed March 27, 2019.
5. The Cure Parkinson’s Trust and Parkinson’s community mourn the loss of their champion Tom Isaacs. Cure Parkinson’s Trust. June 19, 2017. www.cureparkinsons.org.uk/news/cpt-pd-community-mourns-the-loss. Accessed March 14, 2019; Ethics. University of Notre Dame Center for Stem Cells and Regenerative Medicine. https://stemcell.nd.edu/ethics. Accessed March 27, 2019; No research justifies the use of human embryos, Pope Francis says. Catholic News Agency. May 18, 2017. www.catholicnewsagency.com/news/no-research-justifies-the-use-of-human-embryos-pope-francis-says-22203. Accessed March 27, 2019.
6. The Cure Parkinson’s Trust and Parkinson’s community mourn the loss of their champion Tom Isaacs. Cure Parkinson’s Trust. June 19, 2017. www.cureparkinsons.org.uk/news/cpt-pd-community-mourns-the-loss. Accessed March 14, 2019.
7. Ibid.; Tom Isaacs memorial. World Parkinson Coalition. www.worldpdcoalition.org/page/TomIsaacs. Accessed March 27, 2019.
8. Grisales C. Veterans, families demand that EPA ban toxic chemical found in tap water at US military bases. Stars and Stripes. August 1, 2018. www.stripes.com/news/veterans-families-demand-that-epa-ban-toxic-chemical-found-in-tap-water-at-us-military-bases-1.540501. Accessed February 11, 2019.
9. Ibid.
10. Returning EPA to its core mission. US Environmental Protection Agency. www.epa.gov/home/returning-epa-its-core-mission. Updated July 6, 2018. Accessed March 27, 2019.
11. Falce A. Congress increases research funding, shows support for care partners. FoxFeed Blog. September 28, 2018. www.michaeljfox.org/news/congress-increases-research-funding-shows-support-care-partners. Accessed June 28, 2019.
12. Intel co-founder Andrew S. Grove dedicates portion of his estate, up to $40 million, to Michael J. Fox Foundation [press release]. The Michael J. Fox Foundation. January 10, 2008. www.michaeljfox.org/publication/intel-co-founder-andrew-s-grove-dedicates-portion-his-estate-40-million-michael-j-fox. Accessed June 28, 2019.
13. Reuters. Intel pioneer and Holocaust survivor Andy Grove dies at 79. Haaretz. March 22, 2016. www.haaretz.com/jewish/intel-pioneer-and-holocaust-survivor-andy-grove-dies-at-79-1.5421022. Accessed March 27, 2019; Newton C. Legendary former Intel CEO Andy Grove is dead at 79. The Verge. March 21, 2016. www.theverge.com/2016/3/21/11280004/andy-grove-intel-ceo-dies. Accessed March 27, 2019.
14. Andrew Grove. Wikipedia. https://en.wikipedia.org/wiki/Andrew_Grove. Updated February 10, 2019. Accessed February 11, 2019.
15. Dolan KA. Andy Grove’s last stand. Forbes. January 11, 2008. www.forbes.com/forbes/2008/0128/070.html#462dbe0b641e. Accessed June 28, 2019.
16. Ibid.
17. Pollack A, Levy J. The New York Times: Andy Grove’s prescription for health care. FoxFeed Blog. November 18, 2009. www.michaeljfox.org/news/new-york-times-andy-groves-prescription-health-care. Accessed June 28, 2019.
18. Olavsrud T. Intel turns to wearables, big data to fight Parkinson’s. CIO.com. October 28, 2014. www.cio.com/article/2839555/intel-turns-to-wearables-big-data-to-fight-parkinsons.html. Accessed March 28, 2019; Ungerleider N. Why Intel and The Michael J. Fox Foundation are teaming up to create wearable tech for Parkinson’s. Fast Company. August 15, 2014. www.fastcompany.com/3034433/why-intel-and-the-michael-j-fox-foundation-are-teaming-up-to-create-wearable-tech-for-parkin. Accessed March 28, 2019.
19. Andy Grove: we remember six key facts about the former Intel CEO and visionary. NexChange. 2016. https://nexchange.com/article/9009. Accessed March 28, 2019.
20. McGregor J. This moving tribute explains why former Intel CEO Andy Grove was revered by so many. Washington Post. March 22, 2016. www.washingtonpost.com/news/on-leadership/wp/2016/03/22/this-moving-tribute-explains-why-former-intel-ceo-andy-grove-was-so-revered-by-so-many/?noredirect=on&utm_term=.3ba0dee8f248. Accessed June 28, 2019.
21. Goetz CG, Stebbins GT, Wolff D, et al. Testing objective measures of motor impairment in early Parkinson’s disease: feasibility study of an at-home testing device. Movement Disorders. 2009;24(4):551–556.
22. Shinal J. Andy Grove remembered as “bridge builder.” USA Today. June 20, 2016.
23. Michael J. Fox Foundation for Parkinson’s Research. Tuck School of Business at Dartmouth. http://mytuck.dartmouth.edu/show_module_fw2.aspx?sid=1353&gid=5&control_id=11858&nologo=1&cvprint=1&page_id=4475&crid=0&viewas=user. Accessed March 28, 2019.
24. Teichholtz H. The Michael J. Fox Foundation mourns passing of Andy Grove. FoxFeed Blog. March 22, 2016. www.michaeljfox.org/news/michael-j-fox-foundation-mourns-passing-andy-grove. Accessed June 28, 2019.
25. McGregor J. This moving tribute explains why former Intel CEO Andy Grove was revered by so many. Washington Post. March 22, 2016. www.washingtonpost.com/news/on-leadership/wp/2016/03/22/this-moving-tribute-explains-why-former-intel-ceo-andy-grove-was-so-revered-by-so-many/?noredirect=on&utm_term=.3ba0dee8f248. Accessed June 28, 2019; Program information. Andy Grove Scholarship for Intel Employees’ Children. www.scholarsapply.org/intel/instructions.php. Accessed March 28, 2019; Burgelman R, Meza P. Grove Scholars Program: putting rungs back on the ladder. Stanford Graduate School of Business. 2005. www.gsb.stanford.edu/faculty-research/case-studies/grove-scholars-program-putting-rungs-back-ladder. Accessed March 28, 2019; City College mourns distinguished alumnus Andrew Grove ’60. City College of New York. March 22, 2016. www.ccny.cuny.edu/news/city-college-mourns-distinguished-alumnus-andrew-grove-%E2%80%9960. Accessed March 28, 2019.
26. Kaiser J. Final 2018 budget bill eases biomedical researchers’ policy worries. Science. March 22, 2018. American Association for the Advancement of Science. www.sciencemag.org/news/2018/03/final-2018-budget-bill-eases-biomedical-researchers-policy-worries. Accessed June 27, 2019.
27. Estimates of funding for various research, condition, and disease categories (RCDC). National Institutes of Health. 2018. https://report.nih.gov/categorical_spending.aspx. Updated May 18, 2018. Accessed March 31, 2019; Biomedical Research and Development Price Index. Bureau of Economic Analysis. 2018. https://officeofbudget.od.nih.gov/gbipriceindexes.html. Updated January 2018. Accessed October 15, 2018.
28. Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America. npj Parkinson’s Disease. 2018;4(1):21.
29. Estimates of funding for various research, condition, and disease categories (RCDC). National Institutes of Health. 2018. https://report.nih.gov/categorical_spending.aspx. Updated May 18, 2018. Accessed March 31, 2019; Biomedical Research and Development Price Index. Bureau of Economic Analysis. 2018. https://officeofbudget.od.nih.gov/gbipriceindexes.html. Updated January 2018. Accessed October 15, 2018; Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America. npj Parkinson’s Disease. 2018;4(1):21.
30. Chun D. First sign of Parkinson’s hit Fox during filming. Gainesville Sun. May 15, 2009. www.gainesville.com/news/20090515/first-sign-of-parkinsons-hit-fox-during-filming. Accessed March 28, 2019.
31. Raffalli M. Michael J. Fox: working towards cure for Parkinson’s “one of the great gifts of my life.” CBS News. July 8, 2018. www.cbsnews.com/news/michael-j-fox-working-towards-cure-for-parkinsons-one-of-the-great-gifts-of-my-life. Accessed March 28, 2019.
32. IRS Form 990. The Breast Cancer Research Foundation Inc. 2016. https://projects.propublica.org/nonprofits/display_990/133727250/2017_03_EO%2F13-3727250_990_201606; IRS Form 990. Alzheimer’s Disease & Related Disorders Association, Inc. 2016. www.alz.org/media/Documents/form-990-fy-2017.pdf; IRS Form 990. JDRF International. 2016. https://1x5o5mujiug388ttap1p8s17-wpengine.netdna-ssl.com/wp-content/uploads/2018/01/JDRF-FY2017-990-Tax-Return.pdf; IRS Form 990, Arthritis Foundation Inc. 2016. www.arthritis.org/Documents/Sections/About-Us/2016-National-Office-990.pdf; IRS Form 990. The Michael J. Fox Foundation for Parkinson’s Research. 2016. https://files.michaeljfox.org/2016-990-MJFF.pdf.
33. Nocera J. The Michael J. Fox Foundation gets results: the latest treatment for Parkinson’s disease was made possible by the actor’s audacious mission. Bloomberg. January 23, 2019. www.bloomberg.com/opinion/articles/2019-01-23/parkinson-s-inhaler-the-michael-j-fox-foundation-gets-results. Accessed February 11, 2019.
34. Patel AB, Jimenez-Shahed J. Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date. Neuropsychiatric Disease and Treatment. 2018;14:2955–2964.
35. King S. Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy. 1st ed. University of Minnesota Press; 2008.
36. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872; Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 2012;71(6):776–784; Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281(4):341–346.
37. Kuhl MM. New $6 million program looks at causes of Parkinson’s. FoxFeed Blog. March 22, 2018. www.michaeljfox.org/news/new-6-million-program-looks-causes-parkinsons. Accessed June 28, 2019.
38. State Cancer Profiles. https://statecancerprofiles.cancer.gov. Accessed March 28, 2019.
39. Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Movement Disorders. 2004;19(3):318–323; Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143–151.
40. Parkinson Disease Registry. Utah Department of Health. 2018. www.updr.org. Accessed January 4, 2019; Parkinson’s Disease Registry. Nebraska Department of Health & Human Services. 2015. http://dhhs.ne.gov/publichealth/Pages/ced_parkinsons_index.aspx. Updated February 7, 2018. Accessed January 4, 2019.
41. Tanner CM. California’s Parkinson’s Disease Registry pilot project—coordination center and Northern California ascertainment. Defense Technical Information Center. March 2014. https://apps.dtic.mil/dtic/tr/fulltext/u2/a601866.pdf. Accessed June 28, 2019.
42. California Parkinson’s Disease Registry. California Department of Public Health. Chronic Disease Surveillance and Research Branch (CDSRB). www.cdph.ca.gov/Programs/CCDPHP/DCDIC/CDSRB/Pages/California-Parkinson%27s-Disease-Registry.aspx. Updated October 1, 2018. Accessed October 15, 2018.
43. Parkinson Disease Registry. Utah Department of Health. 2018. www.updr.org. Accessed January 4, 2019; Parkinson’s Disease Registry. Nebraska Department of Health & Human Services. 2015. http://dhhs.ne.gov/publichealth/Pages/ced_parkinsons_index.aspx. Updated February 7, 2018. Accessed January 4, 2019.
44. Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Movement Disorders. 2004;19(3):318–323.
45. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953.
46. Singleton AB, Farrer M, Johnson J, et al. α-synuclein locus triplication causes Parkinson’s disease. Science. 2003;302(5646):841–841.
47. Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44(4):595–600.
48. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nature Reviews Genetics. 2006;7(4):306–318; Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nature Genetics. 2009;41:1308; Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson’s disease. Neuron. 2010;66(5):646–661; Singleton AB, Hardy JA, Gasser T. The birth of the modern era of Parkinson’s disease genetics. Journal of Parkinson’s Disease. 2017;7(Suppl 1):S87–S93.
49. Understanding targeted therapy. American Society of Clinical Oncology. Cancer.net. January 2019. www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy. Accessed March 28, 2019.
50. Jackson SE, Chester JD. Personalised cancer medicine. International Journal of Cancer. 2015;137(2):262–266.
51. Singleton AB, Hardy JA, Gasser T. The birth of the modern era of Parkinson’s disease genetics. Journal of Parkinson’s Disease. 2017;7(Suppl 1):S87–S93.
52. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics. 2004;41(12):937–940.
53. Study goals. Parkinson’s Progression Markers Initiative. www.ppmi-info.org/about-ppmi/study-goals. Accessed March 28, 2019.
54. Access Data & Specimens. Parkinson’s Progression Markers Initiative. www.ppmi-info.org/access-data-specimens. Accessed February 11, 2019.
55. PPMI Clinical Study. The Michael J. Fox Foundation for Parkinson’s Research. www.michaeljfox.org/ppmi-clinical-study. Accessed October 15, 2018.
56. Gash DM, Rutland K, Hudson NL, et al. Trichloroethylene: parkinsonism and complex 1 mitochondrial neurotoxicity. Annals of Neurology. 2008;63(2):184–192.
57. Ibid.
58. Haddad D, Nakamura K. Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson’s disease. FEBS Letters. 2015;589(24 Pt A):3702–3713.
59. Xu L, Pu J. Alpha-synuclein in Parkinson’s disease: from pathogenetic dysfunction to potential clinical application. Parkinson’s Disease. 2016;2016:1720621.
60. Bendor J, Logan T, Edwards RH. The function of α-synuclein. Neuron. 2013;79(6):10.1016/j.neuron.2013.1009.1004.
61. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience. 2006;9(10):1231–1233; Martin I, Kim JW, Dawson VL, Dawson TM. LRRK2 pathobiology in Parkinson’s disease. Journal of Neurochemistry. 2014;131(5):554–565.
62. Martin I, Kim JW, Dawson VL, Dawson TM. LRRK2 pathobiology in Parkinson’s disease. Journal of Neurochemistry. 2014;131(5):554–565.
63. Moses H, Dorsey ER, Matheson DM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294(11):1333–1342; Moses H, Matheson DM, Cairns-Smith S, George BP, Palisch C, Dorsey E. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–189.
64. Moses H, Dorsey ER, Matheson DM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294(11):1333–1342.
65. 2018 PhRMA Annual Membership Survey. Pharmaceutical Research and Manufacturers of America. July 26, 2018. www.phrma.org/report/2018-phrma-annual-membership-survey. Accessed June 28, 2019.
66. Moses H, Dorsey ER, Matheson DM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294(11):1333–1342; Moses H, Matheson DM, Cairns-Smith S, George BP, Palisch C, Dorsey E. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–189.
67. Moses H, Dorsey ER, Matheson DM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294(11):1333–1342.
68. Cannon JR, Greenamyre JT. Gene-environment interactions in Parkinson’s disease: specific evidence in humans and mammalian models. Neurobiology of Disease. 2013;57:38–46.
69. Ibid.
70. Ibid.
71. Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451); Cannon JR, Greenamyre JT. Gene-environment interactions in Parkinson’s disease: specific evidence in humans and mammalian models. Neurobiology of Disease. 2013;57:38–46; Lee J-W, Cannon JR. LRRK2 mutations and neurotoxicant susceptibility. Experimental Biology and Medicine. 2015;240(6):752–759.
72. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry. 1992;55(3):181–184; Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86(6):566–576.
73. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry. 1992;55(3):181–184; Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson’s disease in the community? Journal of Neurology, Neurosurgery & Psychiatry. 2002;73(5):529.
74. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86(6):566–576.
75. MDS-UPDRS. International Parkinson and Movement Disorder Society. July 1, 2008. www.movementdisorders.org/MDS-Files1/PDFs/Rating-Scales/MDS-UPDRS_English_FINAL_Updated_June2019.pdf.
76. Dolan KA. Andy Grove’s last stand. Forbes. January 11, 2008. www.forbes.com/forbes/2008/0128/070.html#462dbe0b641e. Accessed June 28, 2019.
77. Little MA, McSharry PE, Roberts SJ, Costello DA, Moroz IM. Exploiting nonlinear recurrence and fractal scaling properties for voice disorder detection. BioMedical Engineering OnLine. 2007;6(1):23.
78. Little MA, McSharry PE, Hunter EJ, Spielman J, Ramig LO. Suitability of dysphonia measurements for telemonitoring of Parkinson’s disease. IEEE Transactions on Biomedical Engineering. 2009;56(4):1015–1022.
79. Tsanas A, Little MA, McSharry PE, Spielman J, Ramig LO. Novel speech signal processing algorithms for high-accuracy classification of Parkinson’s disease. IEEE Transactions on Biomedical Engineering. 2012;59(5):1264–1271.
80. Little MA, McSharry PE, Hunter EJ, Spielman J, Ramig LO. Suitability of dysphonia measurements for telemonitoring of Parkinson’s disease. IEEE Transactions on Biomedical Engineering. 2009;56(4):1015–1022; Tsanas A, Little MA, McSharry PE, Spielman J, Ramig LO. Novel speech signal processing algorithms for high-accuracy classification of Parkinson’s disease. IEEE Transactions on Biomedical Engineering. 2012;59(5):1264–1271; Tsanas A, Little MA, McSharry PE, Ramig LO. Accurate telemonitoring of Parkinson’s disease progression by noninvasive speech tests. IEEE Transactions on Biomedical Engineering. 2010;57(4):884–893; Tsanas A, Little MA, McSharry PE, Ramig LO. Nonlinear speech analysis algorithms mapped to a standard metric achieve clinically useful quantification of average Parkinson’s disease symptom severity. Journal of the Royal Society Interface. 2011;8(59):842–855.
81. Little MA. A test for Parkinson’s with a phone call [video file]. TEDGlobal 2012. June 2012. www.ted.com/talks/max_little_a_test_for_parkinson_s_with_a_phone_call. Accessed June 28, 2019.
82. Arora S, Venkataraman V, Zhan A, et al. Detecting and monitoring the symptoms of Parkinson’s disease using smartphones: a pilot study. Parkinsonism & Related Disorders. 2015;21(6):650–653.
83. Ibid.
84. Zhan A, Mohan S, Tarolli C, et al. Using smartphones and machine learning to quantify Parkinson disease severity: the mobile Parkinson disease score. JAMA Neurology. 2018;75(7):876–880.
85. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data. 2016;3:160011.
86. McLeonida. ResearchKit demo by Jeff Williams at Apple special event, March 2015 [video file]. YouTube. March 11, 2015. www.youtube.com/watch?v=O0gcEFjQNGk. Accessed June 28, 2019.
87. Dorsey ER, Beck CA, Adams M, et al. Communicating clinical trial results to research participants. Archives of Neurology. 2008;65(12):1590–1595.
88. Writing Group for the NINDS Exploratory Trials in Parkinson Disease Investigators. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584–593.
89. Dorsey ER, Chan Y-FY, McConnell MV, Shaw SY, Trister AD, Friend SH. The use of smartphones for health research. Academic Medicine. 2017;92(2):157–160.
90. Turakhia MP, Desai M, Hedlin H, et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. American Heart Journal. 2019;207:66–75.
91. Farr C. The Apple Watch just got a lot better at tracking symptoms of Parkinson’s disease. CNBC. June 9, 2018. www.cnbc.com/2018/06/09/apple-watch-adds-tech-to-track-parkinsons-disease.html. Updated June 10, 2018. Accessed November 10, 2018.
92. Collaboration with Verily aims to deepen Parkinson’s understanding through digital health tools. FoxFeed Blog. May 9, 2018. www.michaeljfox.org/news/collaboration-verily-aims-deepen-parkinsons-understanding-through-digital-health-tools?collaboration-with-verily-aims-to-deepen-parkinson-understanding-through-digital-health-tools=. Accessed June 28, 2019; About the study. Personalized Parkinson Project. www.parkinsonopmaat.nl/studie. Accessed May 20, 2019.
93. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology. 2002;59(10):1541–1550; Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurology. 2014;71(5):543–552.
94. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25(2):420–428; Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K. The first frontier: digital biomarkers for neurodegenerative disorders. Digital Biomarkers. 2017;1(1):6–13; Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K. Novel methods and technologies for 21st-century clinical trials: a review. JAMA Neurology. 2015;72(5):582–588; CNS drugs take longer to develop and have lower success rates than other drugs [press release]. Tufts Center for the Study of Drug Development. November 4, 2014. https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5aa2bf604192023932fe1561/1520615264660/PR-NOVDEC14.pdf. Accessed June 28, 2019.
95. Dwyer C. Pfizer halts research into Alzheimer’s and Parkinson’s treatments. The Two-Way. January 8, 2018. www.npr.org/sections/thetwo-way/2018/01/08/576443442/pfizer-halts-research-efforts-into-alzheimers-and-parkinsons-treatments. Accessed June 28, 2019.
96. Ibid.
97. Taylor P. Backed by Bain, Pfizer loads prime CNS assets into new biotech. FierceBiotech. October 23, 2018. www.fiercebiotech.com/biotech/embargo-8am-edt-backed-by-bain-pfizer-loads-prime-cns-assets-into-new-biotech. Accessed February 11, 2019.
98. Knabe K. Pfizer’s Parkinson’s drugs will be developed by start-up Cerevel Therapeutics. FoxFeed Blog. October 24, 2018. www.michaeljfox.org/news/pfizers-parkinsons-drugs-will-be-developed-start-cerevel-therapeutics?fbclid=IwAR3Wb4f_I6J4AqORHZCpJZeYCzGAdymx1jSxWVfuZCKTq_-UEWAvY_bHGhI&pfizer-parkinson-drugs-will-be-developed-by-start-up-cerevel-therapeutics=. Accessed June 28, 2019.
99. Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson’s disease clinical trial. Movement Disorders. 2018;33(8):1287–1297.
100. 221AD301 phase 3 study of aducanumab (BIIB037) in early Alzheimer’s disease (ENGAGE). US National Library of Medicine. ClinicalTrials.gov. June 23, 2015. https://clinicaltrials.gov/ct2/show/study/NCT02477800. Updated August 6, 2018. Accessed March 28, 2019; Henriques C. MJFF partners with Verily to use data collection watch in PPMI study to advance Parkinson’s research. Parkinson’s News Today. May 14, 2018. https://parkinsonsnewstoday.com/2018/05/14/mjff-verily-collaborate-advance-parkinsons-research-using-study-watch-ppmi. Accessed March 28, 2019.
101. Little MA. A test for Parkinson’s with a phone call [video file]. TEDGlobal 2012. June 2012. www.ted.com/talks/max_little_a_test_for_parkinson_s_with_a_phone_call. Accessed June 28, 2019.
102. den Brok MGHE, van Dalen JW, van Gool WA, Moll van Charante EP, de Bie RMA, Richard E. Apathy in Parkinson’s disease: a systematic review and meta-analysis. Movement Disorders. 2015;30(6):759–769; Patient advocates respond to the PD pandemic. WPC Blog. December 19, 2017. www.worldpdcongress.org/home/2017/12/15/patient-advocates-respond-to-the-pd-pandemic. Accessed June 28, 2019.
103. Gordon L. With Words as My Oars: Paddling the Parkinson’s Rapids. www.leonoregordonpdspeak.com. Accessed February 11, 2019; Wheatley Alumni Newsletter: Number 25: November 25, 2018. Wheatley School Alumni Association. November 25, 2018. www.wheatleyalumni.org/BlogPost/Blogpost-20181125-25.html. Accessed June 28, 2019.
104. Season 2: Mental Health. ParkinsonTV. July 2018. https://parkinsontv.org/two. Accessed February 11, 2019.
105. What are the odds of dying from. National Safety Council. 2017. www.nsc.org/work-safety/tools-resources/injury-facts/chart. Accessed February 11, 2019.
106. Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72(5):432–438.
107. Mark Morris Dance Group. In memory of Leonore Gordon. Dance for PD. 2017. https://danceforparkinsons.org/photo-credits/permissions/in-memory-of-leonore-gordon. Accessed February 11, 2019.
1. Bates C, Rowell A. Tobacco Explained: The Truth About the Tobacco Industry. Action on Smoking and Health; 1998.
2. Paraquat dichloride. US Environmental Protection Agency. www.epa.gov/ingredients-used-pesticide-products/paraquat-dichloride. Updated May 15, 2019. Accessed May 19, 2019; Paraquat Dichloride: One Sip Can Kill. US Environmental Protection Agency. Pesticide Worker Safety. https://www.epa.gov/pesticide-worker-safety/paraquat-dichloride-one-sip-can-kill. Last updated May 8, 2019. Accessed March 25, 2019.
3. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872; Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson’s disease risk from ambient exposure to pesticides. European Journal of Epidemiology. 2011;26(7):547–555; Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the Central Valley of California. American Journal of Epidemiology. 2009;169(8):919–926; McCormack AL, Thiruchelvam M, Manning-Bog AB, et al. Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of Disease. 2002;10(2):119–127.
4. Pesticide National Synthesis Project: estimated annual agricultural pesticide use. US Geological Survey. https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2015&map=PARAQUAT&hilo=H. Updated September 11, 2018. Accessed March 25, 2019.
5. Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and Federal Facilities. US Environmental Protection Agency. www.epa.gov/enforcement/federal-insecticide-fungicide-and-rodenticide-act-fifra-and-federal-facilities. Updated January 29, 2018. Accessed March 29, 2019.
6. H.R.3817—To cancel the registration of all uses of the pesticide paraquat, and for other purposes. Congress.gov. www.congress.gov/bill/116th-congress/house-bill/3817/committees. Accessed July 19, 2019.
7. Freire C, Koifman S. Pesticide exposure and Parkinson’s disease: epidemiological evidence of association. NeuroToxicology. 2012;33(5):947–971; Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson’s disease in rural California. Environmental Health Perspectives. 2009;117(12):1912–1918; Chen T, Tan J, Wan Z, et al. Effects of commonly used pesticides in China on the mitochondria and ubiquitin-proteasome system in Parkinson’s disease. International Journal of Molecular Sciences. 2017;18(12):2507; Pallotta MM, Ronca R, Carotenuto R, et al. Specific effects of chronic dietary exposure to chlorpyrifos on brain gene expression-a mouse study. International Journal of Molecular Sciences. 2017;18(11):2467; Rauh VA. Polluting developing brains—EPA failure on chlorpyrifos. New England Journal of Medicine. 2018;378(13):1171–1174.
8. Pesticide tolerances: chlorpyrifos. Regulations.gov. www.regulations.gov/document?D=EPA-HQ-OPP-2007-1005-0100. Accessed March 29, 2019.
9. Letters in support of September 2018 Department of Justice action on chlorpyrifos. US Environmental Protection Agency. www.epa.gov/ingredients-used-pesticide-products/letters-support-september-2018-department-justice-action. Updated September 24, 2018. Accessed March 29, 2019.
10. Ibid.
11. Pesticide tolerances: chlorpyrifos. Regulations.gov. www.regulations.gov/document?D=EPA-HQ-OPP-2007-1005-0100. Accessed March 29, 2019; Chlorpyrifos. US Environmental Protection Agency. www.epa.gov/ingredients-used-pesticide-products/chlorpyrifos. Updated September 24, 2018. Accessed March 29, 2019; O’Neill E. This pesticide poisons kids, but it’s still sprayed on Washington orchards. Oregon Public Broadcasting. December 16, 2018. www.opb.org/news/article/washington-orchards-northwest-pesticides-chlorpyrifos. Accessed March 29, 2019.
12. Pesticide information profile: chlorpyrifos. Extension Toxicology Network. September 1993. http://pmep.cce.cornell.edu/profiles/extoxnet/carbaryl-dicrotophos/chlorpyrifos-ext.html. Accessed March 30, 2019.
13. Parrish ML, Gardner RE. Is living downwind of a golf course a risk factor for parkinsonism? Annals of Neurology. 2012;72(6):984–984.
14. Ibid.
15. Wallace G. EPA is ordered to ban farm pesticide chlorpyrifos. CNN. August 9, 2018. www.cnn.com/2018/08/09/politics/epa-court-order-ban-pesticide-chlorpyrifos/index.html. Accessed March 30, 2019.
16. Ibid.
17. Chlorpyrifos. US Environmental Protection Agency. www.epa.gov/ingredients-used-pesticide-products/chlorpyrifos. Updated September 24, 2018. Accessed March 29, 2019; Cama T. Trump admin appeals ruling ordering EPA to ban pesticide. The Hill. September 24, 2018. https://thehill.com/policy/energy-environment/408173-trump-admin-appeals-ruling-ordering-epa-to-ban-pesticide. Accessed March 30, 2019.
18. California to ban controversial pesticide blamed for harming child brain development. CBS News. May 8, 2019. www.cbsnews.com/news/california-bans-chlorpyrifos-pesticide-agriculture-state-child-brain-development. Accessed May 20, 2019.
19. Friedman L. E.P.A. won’t ban chlorpyrifos, pesticide tied to children’s health problems. New York Times. July 18, 2019. www.nytimes.com/2019/07/18/climate/epa-chlorpyrifos-pesticide-ban.html?smid=nytcore-ios-share. Accessed July 19, 2019.
20. www.congress.gov/bill/116th-congress/house-bill/230.
21. Rauh VA, Garfinkel R, Perera FP, et al. Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first 3 years of life among inner-city children. Pediatrics. 2006;118(6):e1845–e1859.
22. Ibid.
23. Rauh VA. Polluting developing brains—EPA failure on chlorpyrifos. New England Journal of Medicine. 2018;378(13):1171–1174.
24. Hertz-Picciotto I, Sass JB, Engel S, et al. Organophosphate exposures during pregnancy and child neurodevelopment: recommendations for essential policy reforms. PLOS Medicine. 2018;15(10):e1002671.
25. Roser M, Ritchie H. Fertilizer and pesticides. Our World in Data. https://ourworldindata.org/fertilizer-and-pesticides. Accessed March 25, 2019.
26. McCord CP. Toxicity of trichloroethylene. Journal of the American Medical Association. 1932;99(5):409.
27. Risk management for trichloroethylene (TCE). US Environmental Protection Agency. www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-trichloroethylene-tce. Updated December 14, 2017. Accessed November 16, 2018.
28. Case studies on safer alternatives for solvent degreasing applications. US Environmental Protection Agency. www.epa.gov/p2/case-studies-safer-alternatives-solvent-degreasing-applications. Updated November 28, 2017. Accessed March 30, 2019.
29. Kaplan S. In reversal, chemicals are cleared for use. New York Times. December 20, 2017:A16.
30. Bjorhus J. Minnesota considers banning TCE following emissions problem in White Bear Township. Star Tribune. March 15, 2019.
31. Water gremlin: trichloroethylene (TCE) area of concern. Minnesota Pollution Control Agency. www.pca.state.mn.us/air/water-gremlin-trichloroethylene-tce-area-concern. Accessed March 30, 2019.
32. Ibid.
33. Bjorhus J. Minnesota considers banning TCE following emissions problem in White Bear Township. Star Tribune. March 15, 2019; Reilly M. Legislature may ban widely used solvent TCE after chemical leak at Minnesota manufacturer. Minneapolis/St. Paul Business Journal. March 15, 2019. www.bizjournals.com/twincities/news/2019/03/15/legislature-may-ban-widely-used-solvent-tce-after.html. Accessed June 28, 2019.
34. Kinney DK, Barch DH, Chayka B, Napoleon S, Munir KM. Environmental risk factors for autism: do they help cause de novo genetic mutations that contribute to the disorder? Medical Hypotheses. 2010;74(1):102–106; Kalkbrenner AE, Schmidt RJ, Penlesky AC. Environmental chemical exposures and autism spectrum disorders: a review of the epidemiological evidence. Current Problems in Pediatric and Adolescent Health Care. 2014;44(10):277–318.
35. Superfund: National Priorities List. US Environmental Protection Agency. www.epa.gov/superfund/superfund-national-priorities-list-npl. Updated on June 4, 2018. Accessed January 9, 2019.
36. Wertz J. EPA vows to speed cleanup of toxic Superfund sites despite funding drop [transcript]. National Public Radio. October 11, 2017. www.npr.org/2017/10/11/554564288/epa-vows-to-speed-cleanup-of-toxic-superfund-sites-despite-funding-drop. Accessed June 28, 2019.
37. Anderson B. Taxpayer dollars fund most of the oversight and cleanup costs at Superfund sites. Washington Post. September 20, 2017. www.washingtonpost.com/national/taxpayer-dollars-fund-most-oversight-and-cleanup-costs-at-superfund-sites/2017/09/20/aedcd426-8209-11e7-902a-2a9f2d808496_story.html?utm_term=.ed42f9287636. Accessed June 28, 2019.
38. Bienkowski B. Carcinogenic chemical spreads beneath American town. Scientific American. September 3, 2013. www.scientificamerican.com/article/carcinogenic-chemical-spreads-beneath-american-town. Accessed June 28, 2019.
39. Background on drinking water standards in the Safe Drinking Water Act (SDWA). US Environmental Protection Agency. www.epa.gov/dwstandardsregulations/background-drinking-water-standards-safe-drinking-water-act-sdwa. Updated February 8, 2017. Accessed March 30, 2019.
40. Ibid.
41. Perlman H. Contamination in U.S. private wells. US Geological Survey. http://water.usgs.gov/edu/gw-well-contamination.html. Updated December 2, 2016. Accessed March 30, 2019.
42. Trichloroethylene (TCE) contamination in public water systems nationwide: 2015. Environmental Working Group. www.ewg.org/interactive-maps/2018-tce. Accessed March 30, 2019.
43. Protect your home’s water. US Environmental Protection Agency. www.epa.gov/privatewells/protect-your-homes-water#welltestanchor. Updated December 15, 2017. Accessed March 29, 2019.
44. Sharp R, Pestano JP. Water treatment contaminants. Environmental Working Group. February 27, 2013. www.ewg.org/research/water-treatment-contaminants. Accessed March 30, 2019.
45. Choosing home water filters and other water treatment systems. Centers for Disease Control and Prevention. www.cdc.gov/healthywater/drinking/home-water-treatment/water-filters/step2.html. Updated June 3, 2014. Accessed March 30, 2019.
46. Ibid.
47. Patient groups applaud spending bill that funds important neuro data system. National Multiple Sclerosis Society. September 28, 2018. www.nationalmssociety.org/About-the-Society/News/Patient-Groups-Applaud-Spending-Bill-That-Funds-Im. Accessed January 4, 2019.
48. Farmers, ranchers, and other agricultural managers. US Bureau of Labor Statistics. Occupational Outlook Handbook. www.bls.gov/ooh/management/farmers-ranchers-and-other-agricultural-managers.htm. Accessed March 30, 2019.
49. Damalas CA, Koutroubas SD. Farmers’ exposure to pesticides: toxicity types and ways of prevention. Toxics 2016;4(1):1.
50. Ibid.
51. Ibid.
52. Pesticide information profile: paraquat. Extension Toxicology Network. September 1993. http://pmep.cce.cornell.edu/profiles/extoxnet/metiram-propoxur/paraquat-ext.html. Accessed March 25, 2019.
53. Furlong M, Tanner CM, Goldman SM, et al. Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson’s disease. Environment International. 2015;75:144–150.
54. Ibid.; Damalas CA, Koutroubas SD. Farmers’ exposure to pesticides: toxicity types and ways of prevention. Toxics 2016;4(1):1.
55. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80(22):2035–2041; Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 2012;71(6):776–784; Bale AS, Barone S, Scott CS, Cooper GS. A review of potential neurotoxic mechanisms among three chlorinated organic solvents. Toxicology and Applied Pharmacology. 2011;255(1):113–126.
56. Trichloroethylene. US Environmental Protection Agency. April 1992. www.epa.gov/sites/production/files/2016-09/documents/trichloroethylene.pdf. Updated January 2000. Published 1992. Accessed March 28, 2019; Risk management for trichloroethylene (TCE). US Environmental Protection Agency. www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-trichloroethylene-tce. Updated December 14, 2017. Accessed November 16, 2018.
57. Trichloroethylene toxicity: where is trichloroethylene found? Agency for Toxic Substances & Disease Registry. November 8, 2007. www.atsdr.cdc.gov/csem/csem.asp?csem=15&po=5. Accessed March 30, 2019.
58. Trichloroethylene. National Toxicology Program. November 2016. www.niehs.nih.gov/health/materials/tce_508.pdf; OSH answers fact sheets: trichloroethylene. Canadian Centre for Occupational Health and Safety. www.ccohs.ca/oshanswers/chemicals/chem_profiles/trichloroethylene.html. Updated January 3, 2017. Accessed March 30, 2019.
59. Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS. Welding-related parkinsonism. Neurology. 2001;56(1):8; Sadek AH, Rauch R, Schulz PE. Parkinsonism due to manganism in a welder. International Journal of Toxicology. 2003;22(5):393–401; Flynn MR, Susi P. Neurological risks associated with manganese exposure from welding operations—a literature review. International Journal of Hygiene and Environmental Health. 2009;212(5):459–469.
60. Welders, cutters, solderers, and brazers. US Bureau of Labor Statistics. Occupational Outlook Handbook. www.bls.gov/ooh/production/welders-cutters-solderers-and-brazers.htm. Accessed March 30, 2019.
61. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. New England Journal of Medicine. 2013;368(14):1279–1290; Singh RB, Dubnov G, Niaz MA, et al. Effect of an indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. The Lancet. 2002;360(9344):1455–1461.
62. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Annals of Neurology. 2001;50(1):56–63; Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20):2674–2679.
63. Haspel T. The truth about organic produce and pesticides. Daily Gazette. May 23, 2018.
64. Blackwell DL, Clarke TC. State variation in meeting the 2008 federal guidelines for both aerobic and muscle-strengthening activities through leisure-time physical activity among adults aged 18–64: United States, 2010–2015. National Health Statistics Report. 2018;Jun(112):1–22.
65. Schenkman M, Moore CG, Kohrt WM, et al. Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurology. 2018;75(2):219–226; Miller Koop M, Rosenfeldt AB, Alberts JL. Mobility improves after high intensity aerobic exercise in individuals with Parkinson’s disease. Journal of the Neurological Sciences. 2019;399:187–193.
66. Snijders AH, van Kesteren M, Bloem BR. Cycling is less affected than walking in freezers of gait. Journal of Neurology, Neurosurgery & Psychiatry. 2012;83(5):575–576.
67. Hootman JM, Dick R, Agel J. Epidemiology of collegiate injuries for 15 sports: summary and recommendations for injury prevention initiatives. Journal of Athletic Training. 2007;42(2):311–319.
68. Gates RM. Duty: Memoirs of a Secretary at War. Rpt. ed: Vintage; 2015.
69. National Center for Injury Prevention and Control. Report to Congress on Mild Traumatic Brain Injury in the United States: Steps to Prevent a Serious Public Health Problem. Centers for Disease Control and Prevention; September 2003; National Center for Injury Prevention and Control. Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation. Centers for Disease Control and Prevention; 2015; The CDC, NIH, DoD, and VA Leadership Panel. Report to Congress on Traumatic Brain Injury in the United States: Understanding the Public Health Problem among Current and Former Military Personnel. Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Department of Defense (DoD), and the Department of Veterans Affairs (VA); 2013.
70. McCrea M. Mild Traumatic Brain Injury and Postconcussion Syndrome: The New Evidence for Diagnosis and Treatment. Oxford University Press; 2008; Mac Donald CL, Johnson AM, Cooper D, et al. Detection of blast-related traumatic brain injury in U.S. military personnel. New England Journal of Medicine. 2011;364(22):2091–2100; Levin HS, Diaz-Arrastia RR. Diagnosis, prognosis, and clinical management of mild traumatic brain injury. Lancet Neurology. 2015;14(5):506–517; Andrews PJD, Sinclair HL, Rodriguez A, et al. Hypothermia for intracranial hypertension after traumatic brain injury. New England Journal of Medicine. 2015;373(25):2403–2412.
71. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurology. 2017;16(12):987–1048.
72. Mission and goals. National Institutes of Health. www.nih.gov/about-nih/what-we-do/mission-goals. Updated July 27, 2017. Accessed March 30, 2019.
73. Marar M, McIlvain NM, Fields SK, Comstock RD. Epidemiology of concussions among United States high school athletes in 20 sports. American Journal of Sports Medicine. 2012;40(4):747–755; Lincoln AE, Caswell SV, Almquist JL, Dunn RE, Norris JB, Hinton RY. Trends in concussion incidence in high school sports: a prospective 11-year study. American Journal of Sports Medicine. 2011;39(5):958–963; Hootman JM, Dick R, Agel J. Epidemiology of collegiate injuries for 15 sports: summary and recommendations for injury prevention initiatives. Journal of Athletic Training. 2007;42(2):311–319.
74. Moses H, Matheson DM, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–189.
75. Accelerating Medicines Partnership (AMP): Parkinson’s disease. US Department of Health & Human Services. www.nih.gov/research-training/accelerating-medicines-partnership-amp/parkinsons-disease. Updated October 26, 2018. Accessed February 8, 2019.
76. Alzheimer’s and dementia: facts and figures. Alzheimer’s Association. www.alz.org/alzheimers-dementia/facts-figures. Accessed February 8, 2019.
77. Pfizer ends research for new Alzheimer’s, Parkinson’s drugs. Reuters. January 7, 2018. www.reuters.com/article/us-pfizer-alzheimers/pfizer-ends-research-for-new-alzheimers-parkinsons-drugs-idUSKBN1EW0TN. Accessed January 4, 2019.
78. Dunn A. Pfizer, Bain Capital launch neuroscience company backed with $350M. BioPharma Dive. October 23, 2018. www.biopharmadive.com/news/pfizer-bain-capital-neuroscience-Cerevel/540359. Accessed February 8, 2019.
79. Moses H, Matheson DM, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–189.
80. American Parkinson Disease Association. www.apdaparkinson.org/about-apda. Accessed March 30, 2019.
81. Brian Grant Foundation. https://briangrant.org. Accessed March 30, 2019.
82. Parkinson’s Foundation 2017 Annual Report. Parkinson’s Foundation; 2017.
83. Impact of the Ice Bucket Challenge. ALS Association. www.alsa.org/fight-als/ibc-infographic.html. Accessed February 8, 2019.
84. ACT UP New York. www.actupny.org. Accessed March 30, 2019.
85. ParkinsonNet. www.parkinsonnet.info. Accessed January 5, 2019.
86. Okun MS, Ramirez-Zamora A, Foote KD. Neuromedicine service and science hub model. JAMA Neurology. 2018;75(3):271–272.
87. Bloem BR, Rompen L, de Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: a low-cost health care innovation with a systems approach from the Netherlands. Health Affairs. 2017;36:1987–1996.
88. van der Kolk NM, de Vries NM, Penko AL, et al. A remotely supervised home-based aerobic exercise programme is feasible for patients with Parkinson’s disease: results of a small randomised feasibility trial. Journal of Neurology, Neurosurgery & Psychiatry. 2018;89(9):1003.
89. Szanton SL, Leff B, Wolff JL, Roberts L, Gitlin LN. Home-based care program reduces disability and promotes aging in place. Health Affairs. 2016;35(9):1558–1563.
90. Buchanan RJ, Wang S, Huang C, Simpson P, Manyam BV. Analyses of nursing home residents with Parkinson’s disease using the minimum data set. Parkinsonism & Related Disorders. 2002;8(5):369–380; Ornstein KA, Leff B, Covinsky KE, et al. Epidemiology of the homebound population in the United States. JAMA Internal Medicine. 2015;175(7):1180–1186; Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson’s disease. Journal of the American Geriatrics Society. 1996;44(4):394–399.
91. Centers for Medicare & Medicaid Services. Medicare & Home Health Care. US Department of Health and Human Services. October 2017. www.medicare.gov/sites/default/files/2018-07/10969-medicare-and-home-health-care.pdf; Your Medicare coverage. Medicare.gov. www.medicare.gov/coverage/home-health-services. Accessed March 30, 2019.
92. Woods B. By 2020, 90% of world’s population aged over 6 will have a mobile phone: report. The Next Web. November 18, 2014. https://thenextweb.com/insider/2014/11/18/2020-90-worlds-population-aged-6-will-mobile-phone-report. Accessed October 11, 2018.
93. Dorsey ER, Glidden AM, Holloway MR, Birbeck GL, Schwamm LH. Teleneurology and mobile technologies: the future of neurological care. Nature Reviews Neurology. 2018;14:285–297.
94. WHO Model List of Essential Medicines. World Health Organization; April 2015.
95. Clinical trial delays: America’s patient recruitment dilemma. Drug Development Technology. July 18, 2012. www.drugdevelopment-technology.com/features/featureclinical-trial-patient-recruitment. Accessed March 30, 2019.
96. Fox Trial Finder. The Michael J. Fox Foundation for Parkinson’s Research. https://foxtrialfinder.michaeljfox.org. Accessed March 30, 2019.
97. Why Clinical Trials? The Michael J. Fox Foundation for Parkinson’s Research. https://files.michaeljfox.org/WhyClinicalTrials.pdf. Accessed January 3, 2019; Schneider MG, Swearingen CJ, Shulman LM, Ye J, Baumgarten M, Tilley BC. Minority enrollment in Parkinson’s disease clinical trials. Parkinsonism & Related Disorders. 2009;15(4):258–262.
98. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data. 2016;3:160011.
99. Fox Insight. The Michael J. Fox Foundation for Parkinson’s Research. https://foxinsight.michaeljfox.org. Accessed January 6, 2019.
100. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Movement Disorders. 2015;30(12):1600–1611.
101. Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005;294(20):2618–2622.
102. Weintraub A. How to cover Novartis’ $475K CAR-T drug Kymriah? A “new payment model” is the only way, Express Scripts says. FiercePharma. September 22, 2017. www.fiercepharma.com/financials/car-t-and-other-gene-therapies-need-new-payment-model-says-express-scripts. Accessed January 6, 2019; Rosenblatt M, Termeer H. Reframing the conversation on drug pricing. NEJM Catalyst. November 20, 2017. https://catalyst.nejm.org/reframing-conversation-drug-pricing. Accessed June 28, 2019.
103. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics. 2003;3(3):183–205; Hammer PJ. Differential pricing of essential AIDS drugs: markets, politics and public health. Journal of International Economic Law. 2002;5(4):883–912.